Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway
Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has been demonstrated to alleviate non-alcoholic fatty liver disease (NAFLD). However, the underlying mechanism has not been fully elucidated. Increasing evidence suggests that autophagy is involved in the pathogenesis of hepatic ste...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| 格式: | Artigo |
| 语言: | 英语 |
| 出版: |
2020
|
| 在线阅读: | https://doi.org/10.3389/fcell.2020.602574 https://www.frontiersin.org/articles/10.3389/fcell.2020.602574/pdf |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|